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a b s t r a c t
Coronavirus Disease 2019 (COVID-19) can be associated with various neurological manifestations including acute strokes. Hyper acute diagnosis and treatment are key factors which decrease mortality and
morbidity in stroke patients. The COVID-19 pandemic has introduced a great strain on the healthcare system, and as a result clinicians are facing several barriers in diagnosing and treating strokes. Delayed presentation of strokes is a problem as some in the general population defer the decision to seek immediate
medical attention fearing contracting the virus. Also playing a role is the paucity of healthcare professionals available during a pandemic. Recent literature demonstrates the association of acute strokes in young
patients with COVID-19. Lack of clear pathophysiology of the neurological manifestations from COVID-19
intensifies the problem. A thorough examination of the intensive care unit patient has always been a
challenge owing to several factors including use of sedatives, sepsis, uremia, and encephalopathy secondary to medications. Locked-In Syndrome (LIS) secondary to stroke is much more challenging to diagnose as patients are unable to communicate or elicit any motor functions apart from certain ocular
movements. We present the case of a 25 year old patient with no known history of coagulopathy, but
had developed COVID-19 cytokine storm which culminated in LIS secondary to pontine strokes.
Ó 2020 Elsevier Ltd. All rights reserved.

1. Introduction

2. Case description

Coronavirus Disease-19 (COVID-19) is viral illness caused by
the novel severe acute respiratory syndrome coronavirus 2 (SARS
CoV-2) [1]. The virus was initially reported in a patient in Wuhan,
China in December 2019, and it rapidly progressed into a pandemic currently affecting around 180 countries affecting more
than four million patients and causing 200,000 deaths [2]. The
majority of the patients presented with constitutional symptoms
including fevers, myalgias, respiratory symptoms, and gastrointestinal symptoms. Neurological symptoms are less reported, but
a recent study identified around 36.7% of hospitalized patients
had neurological symptoms during the course of illness [3]. There
are numerous reports of acute strokes in patients with COVID-19
[4,5]. To our knowledge, at present time, there is no reported case
of Locked-In Syndrome associated COVID-19. Here we present a
patient who developed LIS as a result of severe SARS CoV-2
infection.

A 25-year old female with past medical history of insulin
dependent diabetes mellitus, and obesity presented to the hospital
with several day history of cough, shortness of breath, fever and
malaise. She had stopped taking her insulin secondary to poor
appetite. Multiple family members were hospitalized for COVID19 illness. Vital signs on presentation were significant for fever of
102°F, heart rate of 103 beats per minute, and oxygen saturation
of 91% on 6L nasal cannula. Initial exam was significant for tachypnea with no respiratory distress. Initial labs were pertinent for
leukocytosis with lymphopenia, elevated ferritin, elevated blood
sugar, and elevated anion gap. Erythrocyte sedimentation rate
(ESR) and C-reactive protein (CRP) were elevated as well. Chest
X-ray revealed bilateral interstitial and alveolar opacities. The
patient was diagnosed with Diabetic keto-acidosis and admitted
to medicine service. SARS-CoV-2 was detected on the nasal swab
specimen. The patient was transferred to the intensive care unit
(ICU) where she had a prolonged course.
The patient’s respiratory status declined the next day requiring
endotracheal intubation with mechanical ventilation. The patient
was initially sedated with Propofol and Morphine, and later

⇑ Corresponding author at: 344 Marshall Dr S., Apt 1 D, Brooklyn, NY 11209, USA.
E-mail address: aavula@northwell.edu (A. Avula).
https://doi.org/10.1016/j.jocn.2020.07.014
0967-5868/Ó 2020 Elsevier Ltd. All rights reserved.

A. Avula et al. / Journal of Clinical Neuroscience 79 (2020) 80–83

required midazolam to attain appropriate levels of sedation. She
required neuromuscular blocking agents for ventilator dyssynchrony initially as a continuous infusion followed by intermittent
doses. A five day course of hydroxycholoroquine 400 mg daily,
seven day corticosteroids course and a single dose of Tociluzumab
400 mg were given. Despite this, the cytokine storm persisted and
the patient deteriorated quickly leading to multi-organ dysfunction requiring renal replacement therapy.
The patient failed spontaneous awakening trials initially due to
tachypnea, tachycardia and ventilator dyssynchrony. As her respiratory status improved requiring minimal ventilator support,
patient was eventually weaned off all sedation and placed on intermittent sedation. On hospital day-13 a more detailed neurological
exam revealed that patient was able to follow commands through
eye blinking and horizontal eye movement, but was unable to
exhibit any other motor functions. Babinski sign was positive bilaterally. National Institute of Health Stroke Scale was calculated to
be 27.
Computerized Tomography (CT) of the head did reveal any
acute findings. Electroencephalogram and lumbar puncture
(Table 1) failed to identify an etiology for the patient’s neurological
state. Lumbar puncture sample did not detect SARS CoV-2. A Mag-
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netic Resonance Imaging (MRI) of the head revealed multiple foci
of restricted diffusion within the pons, correlating with FLAIR signal abnormality (Figs. 1, 2) consistent with acute pontine ischemic
infarcts. Magnetic Resonance Angiography (MRA) of head and neck
showed decreased flow in distal right vertebral artery but a patent
basilar artery (Fig. 3). Based on clinical findings and neuroimaging,
the patient was diagnosed with Locked-In Syndrome (LIS). Neuroendovascular intervention was deferred as there was no acute
thrombus on the angiography; and heparin therapy was initiated

Table 1
CSF studies.
CSF Laboratory value

Results

Total nucleated cell count
Appearance
RBC count
LDH
Protein
Glucose
COVID-19
NMDA-R Ab
CASPR2-IgG
GAD65 Ab
GABA-B-R Ab
Anti-Neuronal Nuclear Ab
Anti-Glial Nuclear Ab
Purkinje Cell Cytoplasmic Ab
Amphiphysin Ab
DPPX Ab

3
Clear
600
18
23
149
Not detected
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative

Fig. 1. MRI brain-DWI sequences showing acute bilateral pontine strokes.

Fig. 2. MRI brain-T2 Flair showing pontine hyper intensities.

Fig. 3. MRA head showing decreased flow in distal right vertebral artery but patent
basilar artery.
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Fig. 4. Trend of inflammatory markers and D-Dimer. Arrow represents the day of stroke diagnosis. The inflammatory markers trended while the D-dimer was trending up
close to the stroke.

for anticoagulation. The patient did not have a history of coagulopathy, and given her young age it was believed the etiology of
her stroke was secondary to COVID-19. The trend of inflammatory
markers and D-Dimer in the patient is shown in Fig. 4.
3. Discussion
Locked in Syndrome (LIS) is a rare but devastating condition
caused by damage to bilateral corticospinal, corticobulbar and corticopontine tracts of ventral brain stem. Characteristically these
patients are quadriplegic, often with aphasia and dysphagia
despite being fully conscious and cognitive [6,7]. The majority of
patients retain the ability to move the eyes and the ability to blink,
while others are able to retain minimal voluntary movements of
face, tongue and limbs. The most common etiology of LIS is acute
ischemic or hemorrhagic strokes of the brain stem [8].
4. Pathophysiology of LIS in COVID-19
Multiple reports have demonstrated that patients with COVID19 disease may develop acute strokes [3–5]. An observational
study from Netherlands showed that almost 31% of ICU patients
with COVID-19 had thrombotic complications, among which 3.7%
had developed acute strokes [9]. Several reports of pulmonary
embolism and acute myocardial infarction from COVID-19 are
reported as well [10–12]. There are multiple reports of numerous
infarcts and detection of antiphospholipid antibodies in patients
with COVID-19 [13,14]. While the natural history of COVID-19 disease varies, patients with severe COVID-19 are more likely to have
elevated D-dimer levels and thrombocytopenia compared to
patients who developed a more mild course of COVID-19 [15,16].
Shorter clot formation times and higher maximum clot firmness
reflecting hypercoagulable thromboelastographic profiles have
been noted in patients alongside increased fibrinogen and Ddimer [17]. This suggests that fibrin formation and polymerization
may be implicated in vascular thrombosis processes related to
COVID-19 [18].

Angiotensin Converting Enzyme 2 (ACE2) receptors that are
present in various organs including vascular endothelium is the
main site of entry for the virus into human body [19,20]. This
endothelial cell injury mediates inflammatory cell recruitment
and lead to dysregulated release of inflammatory mediators. The
interaction between endothelial cells, macrophages, platelets, lymphocytes after viral binding to endothelial cells play an important
role in activating clotting cascade and hypercoagulability [21].
Apoptosis, endothelial cell damage and necrosis have been seen
in brain tissue on autopsy of patients with the original SARS CoV virus [22].
Virchow’s triad that was first described by Dr. Rudolph Virchow
in 18th century, consists of three contributing factors for thrombus
formation: endothelial injury, stasis and hypercoagulability [23].
Severe COVID-19 disease as described above satisfies two of the
three factors predisposing to thrombus formation. The vast majority of critically ill patients with COVID-19 disease are immobile for
prolonged duration causing blood stasis. This suggests hypercoagulability and thrombi formation to be the most plausible mechanism of ischemic strokes in COVID-19.
5. Diagnostic challenges
Early diagnosis is the key in stroke management given the time
sensitive nature of management. The COVID-19 pandemic makes
this difficult as there is presently a significant burdem on healthcare systems globally. Beyond adequate resources, LIS is a diagnostic challenge as patients are aphasic and cannot follow motor
commands except for eye movements. In the critical care setting,
the challenge intensifies as the patients are usually intubated
and sedated. If a thorough awakening trial and neurological exam
is not conducted, LIS can be easily misdiagnosed as delirium,
encephalopathy, coma or even vegetative state [24]. A detailed
neurological examination is the most important factor for diagnosis. In critically ill patients on mechanical ventilation, society of
critical care medicine guidelines suggests targeting light sedation
or daily interruption of sedation (DSI) [25]. DSI facilitates detailed
assessment of underlying neurological status. DSI is not always tol-
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erated secondary to agitation, discomfort, ventilator dyssynchrony
or encephalopathy as was the case in our patient. MRI is an important diagnostic modality for diagnosis of LIS due to strokes.
6. Treatment
LIS is associated with the very high morbidity. Supportive care,
respiratory hygiene, nutritional support, physical and occupational
therapy are the main stay of treatment in LIS [24]. Speech pathology consultation, eye tracking devices and alphabet boards might
be helpful with communication. In patients with LIS secondary to
acute stroke, treatment aimed at stroke with anticoagulation
and/or antiplatelet agents, cholesterol lowering medications for
primary and secondary prevention should be considered. Full anticoagulation is a matter of debate in patients with COVID-19. A
recent study demonstrated mortality benefit from anticoagulation
in patients on mechanical ventilation [26]. In general, full intensity
anticoagulation is not recommended unless other specific indication for anticoagulation exists [27]. All patients should be on prophylactic anticoagulation if there are no contraindications [27].
Large studies are needed to understand and develop anticoagulation guidelines in COVID-19.
7. Psychosocial and ethical implications
LIS is a tragic disease as patients usually do not have cognitive
deficits and are thus aware of their clinical condition. Severe disability along with intact cognition leads to poor quality of life.
Communicating with a LIS patient is a challenge, and patience
should be practiced when analyzing these patients. Although, studies have noted satisfactory quality of life in LIS survivors; assumptions regarding poor quality of life in LIS could affect management
as clinicians may be biased into less aggressive management
[24,28]. Careful decisions should be made about tracheostomies
and feeding tube placements after communicating with the patient
and their surrogates.
8. Conclusion
The COVID-19 pandemic is a disease with a wide array of presentations. It has the ability to damage several organ systems,
including the nervous system. The development of otherwise rare
strokes, especially in young patients with no coagulopathy history
is likely secondary to the hypercoagulable and hyper-inflammatory
state seen in COVID-19. Patients on mechanical ventilation pose a
challenge for a detailed neurological examination given other
causes of mental status changes such as the use of sedatives, ICU
delirium, along with other confounding factors like uremia,
encephalopathy etc. We recommend daily sedation interruption
trials along with a detailed neurological assessment. Large studies
to establish guidelines regarding anticoagulation in COVID-19
patients are desperately needed.
Conflict of interest
No conflict of interest to be declared for either of the authors.

83

References
[1] Lipsitch M, Swerdlow DL, Finelli L. Defining the epidemiology of Covid-19 –
studies needed. N Engl J Med 2020;382(13):1194–6.
[2] COVID-19
CORONAVIRUS
PANDEMIC.
https://www.worldometers.
info/coronavirus/. Accessed.
[3] Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients
with coronavirus disease 2019 in Wuhan, China. JAMA Neurol 2020.
[4] Avula A, Nalleballe K, Narula N, et al. COVID-19 presenting as stroke. Brain
Behav Immun 2020.
[5] Oxley TJ, Mocco J, Majidi S, et al. Large-vessel stroke as a presenting feature of
Covid-19 in the young. N Engl J Med 2020.
[6] Kenneth Maiese M. Locked-in Syndrome. Merck Manual Professional Version.
http://www.merckmanuals.com/professional/neurologic-disorders/comaand-impaired-consciousness/locked-in-syndrome. Accessed.
[7] Love BB, Biller J. Chapter 22 – Neurovascular system. In: Goetz CG, editor.
Textbook of clinical neurology (third edition). Philadelphia: W.B. Saunders;
2007. p. 405–34.
[8] Khanna K, Verma A, Richard B. ‘‘The locked-in syndrome”: can it be unlocked?.
J Clin Gerontol Geriatrics 2011;2(4):96–9.
[9] Kloka FA, Kruipb MJHA, van der Meerc NJM, Arbousd MS. Incidence of
thrombotic complications in critically ill ICU patients with COVID-19. Thromb
Res 2020.
[10] Siddamreddy S, Thotakura R, Dandu V, Kanuru S, Meegada S. Corona Virus
Disease 2019 (COVID-19) presenting as acute ST elevation myocardial
infarction. Cureus 2020;12(4):e7782.
[11] Danzi GB, Loffi M, Galeazzi G, Gherbesi E. Acute pulmonary embolism and
COVID-19 pneumonia: a random association?. Eur Heart J 2020.
[12] Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in
patients with severe novel coronavirus pneumonia. J Thromb Haemost 2020.
[13] Connell NT, Battinelli EM, Connors JM. Coagulopathy of COVID-19 and
antiphospholipid antibodies. J Thromb Haemost 2020.
[14] Zhang Y, Xiao M, Zhang S, et al. Coagulopathy and antiphospholipid antibodies
in patients with Covid-19. N Engl J Med 2020;382(17):e38.
[15] Chen R, Liang W, Jiang M, et al. Risk factors of fatal outcome in hospitalized
subjects with coronavirus disease 2019 from a nationwide analysis in China.
Chest 2020.
[16] Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019
in China. N Engl J Med 2020;382(18):1708–20.
[17] Tan CW, Low JGH, Wong WH, Chua YY, Goh SL, Ng HJ. Critically Ill COVID-19
infected patients exhibit increased clot waveform analysis parameters
consistent with hypercoagulability. Am J Hematol 2020.
[18] Spiezia L, Boscolo A, Poletto F, et al. COVID-19-related severe
hypercoagulability in patients admitted to intensive care unit for acute
respiratory failure. Thromb Haemost 2020.
[19] Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry
depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease
inhibitor. Cell 2020.
[20] Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019
novel coronavirus in Wuhan, China. Lancet 2020;395(10223):497–506.
[21] Neumann FJ, Marx N, Gawaz M, et al. Induction of cytokine expression in
leukocytes by binding of thrombin-stimulated platelets. Circulation 1997;95
(10):2387–94.
[22] Xiang-Hua Y, Le-Min W, Ai-Bin L, et al. Severe acute respiratory syndrome and
venous thromboembolism in multiple organs. Am J Respir Crit Care Med
2010;182(3):436–7.
[23] Bagot CN, Arya R. Virchow and his triad: a question of attribution. Br J
Haematol 2008;143(2):180–90.
[24] Laureys S, Pellas F, Van Eeckhout P, et al. The locked-in syndrome: what is it
like to be conscious but paralyzed and voiceless?. Prog Brain Res
2005;150:495–511.
[25] Devlin JW, Skrobik Y, Gélinas C, et al. Executive summary: clinical practice
guidelines for the prevention and management of pain, agitation/sedation,
delirium, immobility, and sleep disruption in adult patients in the ICU. Crit
Care Med 2018;46(9):1532–48.
[26] Paranjpe I, Fuster V, Lala A, et al. Association of treatment dose anticoagulation
with in-hospital survival among hospitalized patients with COVID-19. J Am
Coll Cardiol 2020.
[27] Connors JM, Levy JH. COVID-19 and its implications for thrombosis and
anticoagulation. Blood 2020.
[28] Rousseau MC, Baumstarck K, Alessandrini M, Blandin V, Billette de Villemeur T,
Auquier P. Quality of life in patients with locked-in syndrome: evolution over a
6-year period. Orphanet J Rare Dis 2015;10:88.

